Analysis of a novel gene and beta-galactosidase isozyme from a psychrotrophic Arthrobacter isolate.

J Bacteriol

Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, USA.

Published: April 1995

We have characterized a new psychrotrophic Arthrobacter isolate which produces beta-galactosidase isozymes. When DNA from this isolate was transformed into an Escherichia coli host, we obtained three different fragments, designated 12, 14, and 15, each encoding a different beta-galactosidase isozyme. The beta-galactosidase produced from fragment 12 was of special interest because the protein subunit was smaller (about 71 versus 116 kDa) than those typically encoded by the lacZ family. The isozyme encoded by fragment 12 was purified, and its activity and thermostability were examined. Although the enzyme is highly specific towards beta-D-galactoside substrates, its levels in the isolate do not increase in cells grown with lactose. Nucleotide sequence determination showed that the gene encoding isozyme 12 is not similar to the other members of the lacZ family but has regions similar to beta-galactosidase isozymes from Bacillus stearothermophilus and B. circulans. Addition of the isozyme 12 sequence to the database made it possible to examine these enzymes as possible members of a new, separate family. Our analysis of this new family showed some conserved amino acids corresponding to the lacZ acid-base catalytic region but no homology with the nucleophilic region. On the basis of these comparisons, we designated this a new lacG family.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC176839PMC
http://dx.doi.org/10.1128/jb.177.8.1981-1988.1995DOI Listing

Publication Analysis

Top Keywords

beta-galactosidase isozyme
8
psychrotrophic arthrobacter
8
arthrobacter isolate
8
beta-galactosidase isozymes
8
lacz family
8
beta-galactosidase
5
isozyme
5
family
5
analysis novel
4
novel gene
4

Similar Publications

β-Galactosidase from Bacillus circulans ATCC 31382 (BgaD) is a biotechnologically important enzyme for the synthesis of β-galactooligosaccharides (GOS). Among its four isoforms, isoform A (BgaD-A) has distinct synthetic properties. Here, we present cryoelectron microscopy (cryo-EM) structures of BgaD-A and compare them with the known X-ray crystal structure of isoform D (BgaD-D), revealing substantial structural divergences between the two isoforms.

View Article and Find Full Text PDF

Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement.

Int J Mol Sci

September 2024

Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Article Synopsis
  • Fabry disease (FD) results from mutations in a specific gene that lead to a deficiency in the enzyme α-galactosidase A, causing harmful substrate accumulation, with symptoms varying widely between male and female patients.
  • Although FD therapies like enzyme replacement therapy (ERT) and chaperone therapy have been available for around 20 years, there is still limited evidence supporting their long-term effectiveness due to diverse patient populations and inconsistencies in study designs.
  • To improve future research on FD treatments, the review suggests better patient matching, international collaboration, and standardized approaches for evaluating treatment effectiveness, including clear recommendations for study outcomes and duration.
View Article and Find Full Text PDF

[What is confirmed in the treatment of Fabry's disease?].

Inn Med (Heidelb)

December 2024

Allgemeine Innere Medizin D sowie Nieren- und Hochdruckkrankheiten und Rheumatologie, Interdisziplinäres Fabry Zentrum (IFAZ), Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland.

Article Synopsis
  • Fabry's disease is a rare genetic disorder linked to the X chromosome, caused by low levels of the enzyme alpha-galactosidase A (AGAL), leading to harmful build-up of globotriaosylceramide in the body's tissues.
  • The condition significantly affects life expectancy, reducing it by approximately 10 years for females and 20 years for males due to serious complications like kidney failure, heart problems, and strokes.
  • Current treatments include enzyme replacement therapy with specific medications administered every two weeks or an oral therapy for certain gene mutations, with ongoing discussions about new guidelines and research to enhance future treatment options.
View Article and Find Full Text PDF

Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis.

J Inherit Metab Dis

September 2024

Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Article Synopsis
  • A study analyzed data from 83 patients with Fabry disease who switched from agalsidase beta to migalastat, focusing on their kidney function, protein levels in urine, and other heart-related measurements.
  • Results showed that kidney function (eGFR) declined more sharply after the switch, with significant differences between classic and late-onset patients.
  • The study highlights variability in patient outcomes post-switch, suggesting the need for ongoing monitoring to manage their health effectively.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!